Back to Forecasting
CORT Forecast Markets
Corcept Therapeutics Incorporated
7
Active Markets
38%
Avg Probability
All Markets
7 markets
Will the FDA grant a resubmission path (not new-trial) for relacorilant Cushing's by 2026-06-30?
55%
Likely Yes
92% agreement
Jun 30, 2026
IG: 0.80
Will Lifyorli Year 1 US revenue annualize above $50M by the Q3 2026 10-Q?
38%
Likely No
92% agreement
Nov 15, 2026
IG: 0.72
Will CORT revise FY2026 revenue guidance below $900M by Q2 2026 earnings?
35%
Likely No
92% agreement
Aug 15, 2026
IG: 0.64
Will the Korlym scripts-vs-tablets gap narrow below 10 percentage points in the Q1 2026 10-Q?
50%
Likely No
92% agreement
May 15, 2026
IG: 0.60
Will a third-party ANDA on mifepristone be filed by year-end 2026?
25%
Likely No
93% agreement
Dec 31, 2026
IG: 0.56
Will Maduck or Mokari file a Form 4 sale below $40 by 2026-09-30?
35%
Likely No
93% agreement
Sep 30, 2026
IG: 0.48
Will MONARCH MASH Phase 2b hit its primary endpoint by year-end 2026?
28%
Likely No
94% agreement
Dec 31, 2026
IG: 0.48
Resolution Timeline
May 15, 2026
Will the Korlym scripts-vs-tablets gap narrow below 10 percentage points in the Q1 2026 10-Q?Prediction: 50%
Jun 30, 2026
Will the FDA grant a resubmission path (not new-trial) for relacorilant Cushing's by 2026-06-30?Prediction: 55%
Aug 15, 2026
Will CORT revise FY2026 revenue guidance below $900M by Q2 2026 earnings?Prediction: 35%
Nov 15, 2026
Will Lifyorli Year 1 US revenue annualize above $50M by the Q3 2026 10-Q?Prediction: 38%